In patients with moderate and severe acute COVID-19, we found decreasing levels of chemerin on the 7th day compared with baseline assessment, with subsequent increase at 28-day follow-up, suggesting the possible role of chemerin in the resolution of inflammation in COVID-19. The gene discussed is RARRES2; the disease is COVID-19.